Studies examining the effects of AAT deficiency and AAT augmentation therapy in circulating immune cells such as monocytes have provided insight into both the pathophysiology of the disease and non-classical anti-inflammatory properties of AAT augmentation therapy. The gene discussed is SERPINA1; the disease is hyperinsulinemic hypoglycemia, familial, 4.